Collegium Pharmaceutical (COLL) Surged Following Record Quarterly Results
Third Avenue Management, a New York City-based investment firm, published its fourth-quarter 2025 investor letter for the “Third Avenue Small-Cap Value Fund.
Collegium Pharmaceutical Inc (COLL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 1,617,349 | $74,883,259 | +2% | 0.12% |
| 2. | Rubric Capital Management David Rosen | 1,496,436 | $69,284,987 | -48% | 0.83% |
| 3. | D E Shaw D. E. Shaw | 653,874 | $30,274,367 | +68% | 0.02% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 543,773 | $25,176,690 | +1513% | 0.01% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 492,360 | $22,796,272 | +77% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.18 | 10,000 | $91,800.00 | 110,227 | 2017-05-12 | Filing | |
| $10.59 | 2,375 | $25,151.25 | 2,375 | 2016-08-12 | Filing | |
| $12.00 | 3,930 | $47,160.00 | 65,270 | 2015-05-12 | Filing | |
| $12.00 | 196,070 | $2,352,840.00 | 3,256,572 | 2015-05-12 | Filing | |
| $12.00 | 150,000 | $1,800,000.00 | 1,887,332 | 2015-05-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $34.92 | 13,976 | $488,099.22 | 77,071 | 2026-03-18 | Filing | |
| $36.65 | 6,224 | $228,109.60 | 91,047 | 2026-03-09 | Filing | |
| $40.99 | 3,559 | $145,879.50 | 71,770 | 2026-03-03 | Filing | |
| $40.36 | 46,417 | $1,873,557.22 | 75,329 | 2026-03-03 | Filing | |
| $48.66 | 6,475 | $315,084.51 | 103,613 | 2025-12-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,099,702 | $236,116,204 | 0% | |
| 2. | 134,690,000 | $190,449,215 | 1.17% | |
| 3. | 2,256,254 | $104,464,562 | 0% | |
| 4. | 1,876,239 | $86,882,042 | 1.36% | |
| 5. | 1,500,072 | $69,453,332 | 0.23% |
News See All
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2025 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2025 Earnings Call Transcript February 26, 2026Collegium Pharmaceutical, Inc. misses on earnings expectations.
Collegium Pharmaceutical, Inc. (COLL) Gains Momentum on Jornay PM, Truist Highlights Robust Pain Portfolio
TheFly reported on February 10 that Truist Securities analyst Les Sulewski raised its price target on COLL to $58 from $55 and gave it a Buy rating. The analyst emphasized the robustness of the company...
7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds
According to research, the U.S.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2025 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2025 Earnings Call Transcript November 6, 2025Collegium Pharmaceutical, Inc. beats earnings expectations.
Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory
We came across a bullish thesis on Collegium Pharmaceutical, Inc. on The Catholic Capitalist’s Substack by Logan Shearer. In this article, we will summarize the bulls’ thesis on COLL.
Collegium Pharmaceutical, Inc. (COLL) to Present 9 Pain Studies at PAINWeek 2025
Collegium Pharmaceutical, Inc.
11 Best Pharma Stocks to Invest in for the Long Term
According to a recent White House announcement, President Trump wrote letters to 17 major pharmaceutical companies outlining the actions they could take to bring the prices of prescription pharmaceuticals...
Collegium Pharmaceutical, Inc. (COLL) Highlights Real-World Evidence at PAINWeek 2025
Collegium Pharmaceutical, Inc.
10 Overlooked Healthcare Stocks to Invest in
Most Americans have endured the frustration of having their health insurance denied, often with no resolution even after contacting carriers by phone and email. This can be changed by Dr.
Hedge Fund Resource Center